Pharsight

1. List of Turalio drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9169250	DAIICHI SANKYO INC	Compounds modulating c-fms and/or c-kit activity and uses therefor	Nov, 2027 (4 years from now)
US8722702	DAIICHI SANKYO INC	Compounds modulating c-fms and/or c-kit activity and uses therefor	Nov, 2027 (4 years from now)
US8404700	DAIICHI SANKYO INC	Compounds modulating c-fms and/or c-kit activity and uses therefor	Nov, 2027 (4 years from now)
US7893075	DAIICHI SANKYO INC	Compounds modulating c-fms and/or c-kit activity and uses therefor	May, 2033 (10 years from now)
US10730876	DAIICHI SANKYO INC	Synthesis of a compound that modulates kinases	May, 2036 (13 years from now)
US9802932	DAIICHI SANKYO INC	Solid forms of a compound modulating kinases	May, 2036 (13 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8461169	DAIICHI SANKYO INC	Compounds modulating c-fms and/or c-kit activity	Apr, 2028 (5 years from now)
US9358235	DAIICHI SANKYO INC	Kinase modulation, and indications therefor	Jun, 2033 (10 years from now)
US10189833	DAIICHI SANKYO INC	Solid forms of a compound modulating kinases	May, 2036 (13 years from now)
US10435404	DAIICHI SANKYO INC	Formulations of a compound modulating kinases	Jul, 2038 (15 years from now)
US10961240	DAIICHI SANKYO INC	Formulations of a compound modulating kinases	Jul, 2038 (15 years from now)
US10941142	DAIICHI SANKYO INC	Formulations of a compound modulating kinases	Jul, 2038 (15 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Aug 2, 2024
ODE* (ODE*)	Aug 2, 2026
Orphan Drug Exclusivity (ODE)	Aug 2, 2026

NCE-1 date: 2023-08-03

Market Authorisation Date: 02 August, 2019

Treatment: Treatment of adult patients with symptomatic tenosynovial giant cell tumor (tgct) associated with severe morbidity or functional limitations and not amenable to improvement with surgery

Dosage: CAPSULE;ORAL